Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC (TOP0801)

This study has been terminated.
(Poor Accrual)
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00787267
First received: November 6, 2008
Last updated: July 24, 2013
Last verified: July 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2013
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)